智通财经APP讯，亿胜生物科技(01061)发布截至2025年12月31日止年度全年业绩，该公司取得营业额18.14亿港元，同比增加8.62%;年内溢利3.18亿港元，同比增加3.54%;每股盈利56.10港仙;拟派末期股息每股0.07港元。
公告称，截至2025年12月31日止年度，眼科为集团营业额贡献约8.35亿港元，较2024年增加8.2%。截至2025年12月31日止年度，外科录得总营业额约8.96亿港元，较2024年增加1.8%。截至2025年12月31日止年度，医疗保健及伙伴服务录得总营业额约8290万港元，较2024年大幅增加350%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.